Preclinical DILI Risk Assessment Strategies: Bile Acid-Dependent Hepatotoxicity & Mitochondrial Toxicity Assays
As part of this year’s SOT Annual Meeting and ToxExpo, we will be including a special presentation as part of our virtual booth experience. So if you are planning to attend the event (March 12th-26th, find details here), be sure to visit virtual booth #2031.
If you will not be attending the SOT Meeting & ToxExpo, you can register below to receive on-demand access to the recorded presentation during the conference.
Hepatotoxicity studies in preclinical development provide key data to de-risking a compound early or screening compounds out that would not meet regulatory scrutiny. Drug-Induced Liver Injury (DILI) incidents account for more than 10% of all cases of acute liver failure, posing a major clinical and regulatory challenge. While the cause of DILI is multifactorial and difficult to predict, there are known mechanisms that can be screened for in preclinical development using in vitro methods.
In cholestasis, bile acid accumulation leads to hepatocyte cytotoxicity, reducing the liver’s ability to function and causing tissue damage. Mitochondrial toxicity impacts cells’ energy source and can further inhibit function. Our cholestatic DILI assessments, including a functional assay and an ROC analysis, and mitochondrial toxicity assay can help you evaluate your compound’s risk of hepatotoxicity.
Keypoints covered will include:
- DILI risk assessment planning and considerations
- Overviews of following studies, including study design and test systems:
- Using functional assay data and ROC analysis together to better predict risk early in Drug Discovery & Development
- Long versus short term assessment in mitochondrial toxicity assay design
Register to receive access to the presentation and a copy of the slides:
About the Presenter:
Madison Knapp is a Marketing Communications Specialist, focused on creating educational and scientific content to communicate SEKISUI XenoTech’s expertise in drug metabolism and drug interaction studies. She received her BS from the University of Missouri – Columbia and became SEKISUI XenoTech’s Scientific Communications Coordinator in 2019 after serving in similar positions at CropLife America, Bond Life Sciences Center and the CAFNR Office of Communications.